Foundation Medicine and Collaborators to Present New Clinical Data on the Application of FoundationOne® in Breast ...

Submitted by Anonymous (not verified) on Wed, 12/03/2014 - 07:30

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Foundation Medicine, Inc. (FMI) today announced that eight abstracts highlighting new clinical data on the application of FoundationOne® in patients with breast cancer will be presented at the 37th Annual San Antonio Breast Cancer Symposium (SABCS) taking place December 9-13, 2014, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

FoundationOne, the company’s flagship clinical test for patients with solid tumors, provides a comprehensive genomic profile that identifies the molecular alterations in a patient’s unique cancer and matches them with relevant targeted therapies and clinical trials. The test also contributes to a large and growing database of molecular information that can be leveraged to gain new insights into the biology and treatment of breast cancer and other solid tumors.

“We look forward to presenting new data on the FoundationOne clinical experience in breast cancer with our collaborators at this year’s SABCS,” said Vincent Miller, M.D., chief medical officer, Foundation Medicine. “We believe these data further demonstrate the clinical utility of FoundationOne in informing the current treatment of patients with breast cancer. These data also show that our comprehensive genomic profiling capabilities can unlock novel insights into the underlying biology of the disease and play an important role in driving the development of future treatment options.”

The schedule for the podium presentation by Foundation Medicine and its collaborators is as follows:

Date & Time: Wednesday, December 10, 2014 at 10:30 a.m. CT
Title: Reduced tumor lymphocytic infiltration in the residual disease (RD) of post-neoadjuvant chemotherapy (NAC) triple-negative breast cancers (TNBC) is associated with Ras/MAPK activation and poorer survival
Session: S1-08. General Session 1
Location: Hall D
Collaborators: Vanderbilt University, Yale University, Peter MacCallum Cancer Center, Charite University, Institute Julies Bordet, WEHI University, Oncosalud, Institute Nacional de Enfermedades Neoplasicas

The schedule for the poster discussion by Foundation Medicine and its collaborators is as follows:

Date & Time: Friday, December 12, 2014 from 5:00-7:00 p.m. CT
Title: Profiling of ESR1-mutated metastatic breast cancers by FoundationOne allows a broad genomic understanding for potential clinical implications.
Session: PD6-5. Targeting Hormone Resistance: ER Mutation & Fusion
Location: Ballroom B
Collaborators: Baylor/Texas Oncology, Case Western, Thomas Jefferson University, Oncology Consultants

The schedule for poster sessions by Foundation Medicine and its collaborators is as follows:

Date & Time: Thursday, December 11, 2014 from 7:30-9:00 a.m. CT
Title: Incidence of actionable genomic alterations in metastatic breast cancer: A prospective study.
Session: P2-03-03. Tumor Cell and Molecular Biology: Genomics
Location: Halls A-B
Collaborator: Ohio State University

Date & Time: Thursday, December 11, 2014 from 7:30-9:00 a.m. CT
Title: FoundationOne profiling of TSC1 and TSC2-mutated advanced breast cancers
Session: P2-03-06. Tumor Cell and Molecular Biology: Genomics
Location: Halls A-B
Collaborators: Baylor University/Texas Oncology

Date & Time: Thursday, December 11, 2014 from 7:30-9:00 a.m. CT
Title: Anastrozole and everolimus in hormone receptor-positive metastatic breast cancer: Safety profile, activity and associations of molecular alterations in the PI3K/AKT/mTOR pathway
Session: P2-05-03. Tumor Cell and Molecular Biology: Molecular Profiles
Location: Halls A-B.
Collaborators: MD Anderson Cancer Center and UC San Diego Moores Cancer Center

Date & Time: Friday, December 12, 2014 from 7:30-9:00 a.m. CT
Title: Activating mutations in ERBB2/HER2 as found by FoundationOne represent potential therapeutic targets in breast cancer
Session: P4-15-03. Treatment: HER2-Targeted Therapy
Location: Halls A-B

Date & Time: Saturday, December 13, 2014 from 7:30-9:00 a.m. CT
Title: Genomic profiling by FoundationOne analysis of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations (GA)
Session: P6-14-02. Treatment: Inflammatory Breast Cancer
Location: Hall C
Collaborators: Thomas Jefferson University Cancer Center and Inflammatory Breast Cancer International Consortium

Date & Time: Saturday, December 13, 2014 from 7:30-9:00 a.m. CT
Title: Enrichment of janus kinase-2 (JAK2)-amplified tumor cell populations in triple-negative breast cancers (TNBC) during chemotherapy treatment
Session: P6-03-03. Tumor Cell and Molecular Biology: Novel/Emerging Therapeutic Targets
Location: Hall C
Collaborators: Vanderbilt University, Harvard University, Oncosalud, Instituto Nacional de Enfermedades Neoplasicas, Houston Methodist Hospital

About FoundationOne®

FoundationOne, the company's first clinical product, is a fully informative genomic profile for solid tumors used by oncologists to identify the molecular alterations in a patient's tumor and match those alterations with relevant targeted therapies and clinical trials. Using next-generation sequencing in routine cancer specimens, FoundationOne interrogates all genes somatically altered in human cancers that are validated targets for therapy or unambiguous drivers of oncogenesis based on current knowledge. It reveals all classes of genomic alterations including base substitutions, insertions, deletions, copy number alterations and select rearrangements. FoundationOne fits easily into the clinical workflow of the ordering physician, and test results are provided in an easy-to-interpret report supported by a comprehensive review of published literature. FoundationOne is a laboratory-developed test performed at Foundation Medicine's CLIA-certified lab. The test is accredited by CAP, is approved by the New York State Department of Health and has received a CE Mark. Please visit www.FoundationOne.com for more information.

About Foundation Medicine

Foundation Medicine (FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, sarcomas and pediatric cancers, provide a fully informative genomic profile to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

Cautionary Note Regarding Forward-Looking Statements for Foundation Medicine

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the clinical utility of FoundationOne in informing the treatment of cancer patients and the ability of FoundationOne to contribute information that will lead to the development of treatment options. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risk that FoundationOne does not perform as expected, and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2013, which is on file with the Securities and Exchange Commission, as well as other risks detailed in subsequent filings with the Securities and Exchange Commission, may be realized. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.